Peptide Research Database
Access 7,487 peer-reviewed studies, clinical trials, and research papers on peptides. Filter by key research, study type, compound, and category. Direct links to full PubMed entries for comprehensive, evidence-based exploration.
The role of antimicrobial polypeptides in predicting urinary tract infection: UTILISE study.
In lab experiments, although insufficient as standalone diagnostic tests, they may serve as useful adjunctive tools to improve diagnostic confidence in children with suspected UTI.
Yildirim ZNY, Afonso AC, Akil I, Aksu B, Alpay H, Atmis B, Aydog O, Bakkaloglu S, Bayazıt AK, Bayram MT, Bilge I, Bulut IK, Comak E, Delebe OC, Demir BK, Dincel N, Donmez O, Durmus MA, Dursun H, Dusunsel R, Duzova A, Ertan P, Gedikbasi A, Goknar N, Guven S, Hacihamdioglu DO, Jankauskiene A, Kalyoncu M, Kavukcu S, Kenan BU, Kucuk N, Kural B, Litwin M, Montini G, Morello W, Obrycki L, Omer B, Ozdemir EM, Ozkayin N, Paripovic D, Pehlivanoglu C, Saygili S, Schaefer F, Schaefer S, Sonmez F, Tabel Y, Tas N, Tasdemir M, Teixeira A, Tekcan D, Topaloglu R, Tulpar S, Turkkan ON, Uysal B, Uysalol M, Vaiciuniene D, Yavuz S, Yel S, Yildirim T, Yildiz N, Yuksel S, Yurtseven E, Yilmaz A
Urinary tract infection (UTI) is among the most common serious bacterial infections in childhood. Antimicrobial polypeptides (AMPs) are key effector molecules of the innate immune system and play a crucial role in protecting against infections. The aim of the study was to assess serum and urinary levels of AMPs to determine their ability to distinguish UTI from non-UTI infection, contamination, asymptomatic bacteriuria and healthy control groups. A total of 520 children between ages 0 and 18 years old with UTI, asymptomatic bacteriuria, contamination, non-UTI infections and healthy controls were participated from 37 pediatric nephrology centers. In all groups, pre-treatment blood and urine samples were obtained before the initiation of antibiotics at the admission. In the UTI group, post-treatment samples were also collected after treatment. Serum and urine levels of cathelicidin, defensin-α, defensin-β, hepcidin, lactoferrin, ribonuclease 7 (RNase7), and secretory leukocyte protease inhibitor were measured by enzyme-linked immunosorbent assay (ELISA) technique. Urinary cathelicidin and β-defensin-2 levels were significantly higher in children with UTI than in all comparator groups (all adjusted p < 0.001). Urinary cathelicidin and β-defensin-2 levels decreased significantly after treatment. Other AMPs did not reliably distinguish UTI from contamination, asymptomatic bacteriuria, or non-UTI infections. ROC analysis showed moderate diagnostic performance for urinary cathelicidin (AUC 0.714) and β-defensin-2 (AUC 0.766). Combining both biomarkers increased specificity (85.4%) but reduced sensitivity (67.5%). Urinary cathelicidin and β-defensin-2 were the most promising biomarkers for pediatric UTI, demonstrating moderate discriminatory ability. Although insufficient as standalone diagnostic tests, they may serve as useful adjunctive tools to improve diagnostic confidence in children with suspected UTI.
Engineering the synovial lining-sublining architecture in a human 3D model to study macrophage-fibroblast interactions in arthritis.
This study found together, these findings establish a spatially organized, xeno-free 3D synovial membrane model as a defined and experimentally tractable platform for studying macrophage-FLS communication and synovial activation.
Gaber T, Pfeiffenberger M, Beissel J, Akil N, Walter-Vogiadji J, Jæhger DE, Maleitzke T, Winkler T, Hoff P, Wiebe E, Buttgereit F, Damerau A
The synovial membrane is a key regulator of joint homeostasis, inflammation, and tissue remodeling, yet humanin vitromodels that reproduce its spatial organization while enabling controlled investigation of macrophage-fibroblast-like stromal cell (FLS) interactions remain limited. Here, we developed a xeno-free, spatially organized 3D synovial membrane model that reconstructs the structural relationship between the macrophage lining and fibroblast-rich sublining compartment. The model was generated by establishing an apically organized macrophage-containing lining-like compartment on a transwell membrane, followed by stepwise assembly of FLS laden hydrogel constructs. Hydrogel screening identified a 1:3 VitroGel® RGD formulation as the most suitable condition to support FLS viability, homogeneous cell distribution, and stable tissue organization. Experimentally induced M1-like and M2-like macrophages were incorporated, and the model was stimulated with TNF-α, TGF-β, or Osteoarthritis (OA) synovial fluid (SF). Cytotoxicity, proliferation, metabolic activity, gene expression, and cytokine secretion were analyzed. Pharmacological responsiveness was evaluated using adalimumab and 4-octyl itaconate (4-OI). The spatially organized construct enabled compartment-specific analysis of macrophage-FLS communication. M1-like macrophages induced inflammatory FLS responses characterized by elevatedIL1B, IL6, TNFA, andMMP1expression, whereas M2-like macrophages promoted matrix-remodeling and myofibroblast-related programs, including increasedTGFBandACTA2expression. Exposure to OA-SF and cytokine stimulation induced FLS hyperproliferation, metabolic adaptation, and distinct transcriptional responses. Treatment with adalimumab suppressed TNF-driven inflammatory responses, whereas 4-OI reduced selected inflammatory markers and altered remodeling-associated responses. Together, these findings establish a spatially organized, xeno-free 3D synovial membrane model as a defined and experimentally tractable platform for studying macrophage-FLS communication and synovial activation. By combining physiologically inspired tissue organization with compartment-specific analysis, the model provides a humanin vitroplatform for investigating OA-associated inflammatory and remodeling processes and evaluating pharmacological modulation under defined experimental conditions.
Travel health needs and medication self-management among travellers using GLP-1-based medicines: a netnographic study.
This study found product-specific prescribing information should inform storage and dosing discussions. Explored travel-health needs, treatment workload, capacity and medication self-management in online accounts of planned and experienced travel.
Daif R, Elsayed K, Bikowski L, Naghavi N
Use of glucagon-like peptide-1 (GLP-1)-based medicines is expanding, while travel-specific evidence remains limited. Travellers must maintain treatment as transport, accommodation, food and daily routines change. This study explored travel-health needs, treatment workload, capacity and medication self-management in online accounts of planned and experienced travel. A qualitative netnographic study examined 129 publicly accessible English-language discussions from Reddit, TripAdvisor and Mumsnet concerning current or recent GLP-1-based medicine use and actual or planned travel. Inductive coding identified reported actions, concerns and adaptations before the Cumulative Complexity Model guided a second interpretive stage. Cross-sectional comparison by travel status described differences in retrieved content, and sensitivity analysis excluded 20 compounded-tirzepatide records. Analysis identified four linked findings: travel-related treatment workload and continuity, practical capacity for medication management, medication self-management and travel adaptations, and a cross-sectional pattern by travel status. Planned/upcoming records contained information seeking in 41/62 (66%) and medication logistics in 35/62 (56%), whereas experienced/current records contained eating and activity adaptation in 45/53 (85%). Suitable storage, itinerary flexibility, prior treatment experience and reliable guidance supported medication management. Travellers either maintained treatment while adapting travel practices or described moving, delaying, reducing or interrupting a dose when treatment and itinerary demands conflicted. GLP-1-based medicines add travel-specific dosing, storage, tolerability, hydration and eating demands to medication-management problems already recognised in travel medicine. Planned and experienced records emphasised different problems, but the groups involved different contributors and do not show within-person change. Pre-travel assessment should address medication and itinerary fit, with treatment changes reviewed by the prescribing clinician and practical travel requirements addressed through authoritative travel-service information. Product-specific prescribing information should inform storage and dosing discussions.
Daily Steps and Heart Rate After Semaglutide or Tirzepatide Initiation: An Apple HealthKit Cohort in All of Us.
Le Q, Dangol G, Maharjan S, Yarlagadda B, Bhandari A
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation.
This study found among adults with overweight or obesity and ASCVD without diabetes, there was no significant difference in cardiovascular risk between semaglutide and tirzepatide.
Aubrac G, Raquib RV, Le MT, Webster-Clark M, Platt RW, Stokes AC
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits remains unknown. The objective was to compare the effectiveness of semaglutide versus tirzepatide on the risk of major adverse cardiovascular events (MACE) in individuals with overweight or obesity and atherosclerotic cardiovascular disease (ASCVD) without diabetes. This active comparator, new user study emulated a trial using national claims data from Komodo Health. Eligible individuals had a history of ASCVD and, within 1 year prior to initiation: BMI ≥ 27 with a diagnosis of overweight or obesity, continuous insurance coverage and no diabetes or contraindications. Prior GLP-1 receptor agonist or obesity medication users were excluded. The primary outcome was a composite of myocardial infarction, stroke, hospitalization for heart failure or unstable angina, coronary revascularization and mortality (revised 5-point MACE). Secondary outcomes included revised 3-point MACE and individual endpoints. Hazard ratios were estimated using Cox models with inverse probability weighting. There was a non-significant difference in risk of revised 5-point MACE (HR = 1.21, 95% CI: 0.99-1.51) or secondary outcomes between semaglutide and tirzepatide. Sensitivity analyses showed directionally consistent point estimates for revised 5-point MACE but highlighted sensitivity to decisions surrounding early events, off-label use, analytic approach and outcome definition. Among adults with overweight or obesity and ASCVD without diabetes, there was no significant difference in cardiovascular risk between semaglutide and tirzepatide.
GLP-1 receptor agonists for people with type 2 diabetes and peripheral artery disease: reducing uncertainty in clinical practice.
In a randomized trial, in the meantime, clinicians should choose a GLP-1RA of proven efficacy in subjects with T2D and PAD to improve their cardio-nephro-metabolic outlook, as well as their walking capacity, limited at present to liraglutide and semaglutide.
Giugliano D, Caruso P, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K
Peripheral artery disease (PAD) may be the most frequent first manifestation of cardiovascular disease (CVD) in type 2 diabetes (T2D). Management of PAD in T2D aims to improve symptoms and lower the high risk of major adverse cardiovascular (MACE) and limb (MALE) events. Drugs commonly used are lipid-lowering and antihypertensive medicines, antithrombotic and antihyperglycemic agents. The ADA recommends both GLP-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) as the first-line therapy to reduce the cardio-renal risk in people with T2D, including those with PAD. Meta-analyses of randomized controlled trials (RCTs) show that semaglutide is better than placebo in reducing by 30% PAD events in people with T2D (with or without PAD at baseline), although no RCT was designed to investigate PAD-related hard outcomes as a primary endpoint; however, both liraglutide and semaglutide may increase walking distance by approximately 25-30 m at six months in people with T2D and PAD. Cohort studies also confirm that GLP-1RA use is better than non-use in reducing by 28% the risk of MALE in individuals with T2D and PAD, although their retrospective design might introduce residual confounding and under-ascertainment of outcomes. Dedicated RCTs will obtain more direct evidence for the promising lower limb benefits of GLP-1RAs, but the scientific outlook of specific RCTs on hard limb events is empty. In the meantime, clinicians should choose a GLP-1RA of proven efficacy in subjects with T2D and PAD to improve their cardio-nephro-metabolic outlook, as well as their walking capacity, limited at present to liraglutide and semaglutide.
Cesarean Myomectomy for Refractory Uterine Atony in an Eclamptic Woman with Multiple Fibroids: A Case Report from the Democratic Republic of Congo.
In a case report, this single observation does not establish the safety or efficacy of the procedure, but suggests that cesarean myomectomy may be considered as a uterus-preserving option in carefully selected patients with refractory uterine atony related to extensive fibromyomatosis, provided that surgical expertise and blood transfusion capacity are available.
Kahinga Mukwiza G, Isango Idi Y, Munan Mwazaz R, Kaki Bal'olam B, Biayi Mukendi J, Tshisola Kashala P, Mbiya Kabukwa Bafwindisoni F, Yowa Malemba Y, Tshinawej Mukinyi P, Katshunga Omalosombe J, Mambue Mwepu N, Kiwele Zongwe E, Chola Mwansa J, Kabamba Nzaji M, Kinenkinda Kalume X
Cesarean myomectomy remains a controversial procedure because of concerns regarding severe hemorrhage and peripartum hysterectomy. Recent reports suggest that it may be performed safely in carefully selected patients; however, the certainty of the available evidence remains very low, and reports describing its use for refractory uterine atony in women with eclampsia are scarce. We report the case of a 38-year-old Congolese woman, gravida 3 para 0 abortus 2, admitted to the University Clinics of Lubumbashi with generalized tonic-clonic seizures, severe hypertension (180/120 mmHg), and marked proteinuria, leading to a diagnosis of eclampsia. No ultrasound examination was performed before surgery because of the maternal emergency. After stabilization with magnesium sulfate and nicardipine, an emergency cesarean section was performed. A live female infant weighing 2030 g was delivered but died 30 minutes after birth in the neonatal intensive care unit. Extensive uterine fibromyomatosis was identified, including nine fibroids, the largest measuring 16 × 10 × 8 cm and weighing approximately 1050 g. After hysterorrhaphy, severe uterine atony persisted despite uterine massage and oxytocin administration. Considering the patient's nulliparity and the wish to preserve the uterus, a conservative cesarean myomectomy was undertaken. Five major fibroids were removed, including the giant lower-segment fibroid. Progressive restoration of uterine tone was observed after myomectomy, with satisfactory hemostasis. Estimated blood loss was 900 mL, and total operative time was 90 minutes. Postoperatively, the patient received blood transfusion and recovered without complications. She was discharged in stable condition on postoperative day five. In this patient, removal of the dominant fibroids was temporally associated with restoration of uterine tone and allowed emergency hysterectomy to be avoided. This single observation does not establish the safety or efficacy of the procedure, but suggests that cesarean myomectomy may be considered as a uterus-preserving option in carefully selected patients with refractory uterine atony related to extensive fibromyomatosis, provided that surgical expertise and blood transfusion capacity are available.
Excessive Intrapancreatic Fat Deposition and the Potential Therapeutic Role of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review.
In a combined analysis of multiple studies, prospective powered trials with standardised imaging and hepatic/visceral fat measurements are needed before clinical practice.
Bilal Azam M, Al Rashid S, Balasubramanian R, Pakkir Maideen NM, Amirthalingam P, Chidambaram K
Excessive intrapancreatic fat deposition, also called non-alcoholic fatty pancreas disease, is marked by abnormal fat accumulation in pancreatic tissue and inked to metabolic syndrome, obesity, insulin resistance, and type 2 diabetes mellitus. Despite its clinical importance, intrapancreatic fat deposition lacks standardized diagnostic criteria and is often underdiagnosed. This systematic review explores the pathogenesis, diagnostic challenges, and clinical relevance of intrapancreatic fat deposition, with particular attention to the therapeutic potential of glucagon-like peptide-1 receptor agonists. A literature search of PubMed, Scopus, and Google Scholar, supplemented by a post-review verification search, identified six studies (two preclinical and four clinical studies) meeting pre-specified eligibility criteria for original data on a glucagon-like peptide-1 receptor agonist intervention with a pancreatic fat outcome, following Preferred Reporting Items for Systematic reviews and Meta-Analyses 2020 guidance; several sources considered during full-text review are reclassified as secondary literature or as not evaluating a glucagon-like peptide-1 receptor agonist and are cited instead as background. Preclinical evidence indicates that liraglutide and semaglutide can attenuate pancreatic endoplasmic reticulum stress, islet-cell apoptosis, and lipid dysregulation in diet-induced obesity models. Clinical evidence is mixed: a retrospective study reported a significant reduction in pancreatic fat with liraglutide in patients with intrapancreatic fat deposition, whereas randomised trials of liraglutide, exenatide, and dulaglutide have not consistently shown a significant between-group reduction, and direct pancreatic fat outcome data for semaglutide in humans are lacking. A 2026 systematic review and meta-analysis of randomised controlled trials across glucose-lowering drug classes reported a significant pooled reduction in intrapancreatic fat deposition with glucagon-like peptide-1 receptor agonists, providing independent, quantitative support for a class effect. Glucagon-like peptide-1 receptor agonists are already established to confer benefits beyond glycaemic control and pancreatic fat, including cardiovascular, renal, and broader weight-related metabolic benefits; their potential role in intrapancreatic fat deposition is one facet of this wider profile rather than a distinct "dual-purpose" mechanism. Given small samples, heterogeneous imaging, and inability to separate pancreas-specific effects from hepatic and visceral fat reductions, evidence suggests an unconfirmed role for glucagon-like peptide-1 receptor agonists in intrapancreatic fat deposition. Prospective powered trials with standardised imaging and hepatic/visceral fat measurements are needed before clinical practice.
Temporal Dosing Tunes Glutathione Gradient across Liver-Blood-Tumor Axes to Boost the Chemotherapeutic Potency of Prodrug Nanoassemblies.
This study found our study highlighted a tumor treatment model based on the synergistic strategy of structural optimization and GSH gradient regulation across the liver-blood-tumor axis to boost the efficacy of chemotherapy.
Zhang Z, Zhang B, Zhang Y, Zheng S, Lu Y, Zhang D, Cui X, Xing J, Sun J, He Z, Sun B, Sun Y
Redox-responsive prodrug nanodelivery systems hold immense promise in cancer therapy, offering advantages of improved pharmacokinetics, enhanced tumor selectivity, and increased safety. However, compared with standard therapeutic formulations, prodrug nanodelivery systems fail to yield superior antitumor efficacy at equivalent doses, attributable to inadequate drug activation and intratumoral accumulation. Herein, the three-in-one drug-release module, comprising an α-disulfide bond, an ethylene glycol moiety, and a short carbon chain, was covalently linked to paclitaxel (PTX) to construct three prodrug nanoassemblies (PSBA10 NPs, PSBA12 NPs, PSBA14 NPs). Notably, PSBA10 NPs, which possessed the shortest carbon chain, exhibited hypersensitive redox-responsive drug release and potentiated antitumor efficacy. Although PSBA10 NPs exhibited better safety than paclitaxel solution (Taxol) at equivalent doses, superior efficacy remained unattainable. Interestingly, a temporal-dose-regulated glutathione (GSH) gradient across the liver-blood-tumor axis increased the intratumoral accumulation of PSBA10 NPs by approximately 3-fold, resulting in pronounced antitumor efficacy superior to Taxol. This transient depletion of GSH in the liver and blood reduced the cleavage of disulfide bonds in the systemic circulation, enhancing tumor accumulation and selective activation of PSBA10 NPs. Our study highlighted a tumor treatment model based on the synergistic strategy of structural optimization and GSH gradient regulation across the liver-blood-tumor axis to boost the efficacy of chemotherapy.
Age-Dependent Alterations in Glutathione Metabolites Following Muscle Injury.
In a mouse study, this suggests that aging negatively influences metabolite profiles within the GSH synthesis pathway.
Fiorucci NA, Seneviratne D, Phan L, Tran LS, Azimychetabi Z, Kavanagh HM, Smith HC, Martic S, Emery RJN, Tobin SW
Age-related impairments in antioxidant defences contribute to delayed tissue repair and increased susceptibility to oxidative stress following muscle injury. Glutathione (GSH), a key cellular antioxidant, plays a central role in redox homeostasis and recovery processes. GSH is synthesized through a sequential process involving glutamic acid and cysteine, catalyzed by the rate-limiting enzyme glutamate cysteine ligase (GCL) to form γ-glutamyl cysteine (γGC), which subsequently combines with glycine to produce GSH. Using metabolomic profiling and acute skeletal muscle injury in mice, this study characterized age-dependent alterations in GSH biosynthesis. Clustering analysis identified that muscle from 12-month-old mice have a delayed GSH synthesis profile in response to injury compared to 3-month-old mice, with an age-dependent delay in γGC accumulation. This suggests that aging negatively influences metabolite profiles within the GSH synthesis pathway. As γGC lies downstream of this enzymatic step, its supplementation may bypass the GCL bottleneck. To test this, C2C12 myoblasts were treated with γGC (from 1-100 µg/mL), however this did not affect myoblast proliferation or differentiation. These data suggest detrimental age-related dysregulation of GSH-related metabolites in skeletal muscle repair, particularly γGC, however further examination of the role of exogenous γGC supplementation in this process is required to identify further therapeutic benefit.